CD4 and colorectal carcinoma: In addition, categorizing CRC patients based on disease stages and identifying the exact CD4+ T cell subpopulations could help in targeting PD-1 in CRC patients in more specific ways, and reduce the side effects of current anti-PD1 antibodies.